Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 27

1.

Evaluation of a calibrated (18)F-FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment.

Herholz K, Westwood S, Haense C, Dunn G.

J Nucl Med. 2011 Aug;52(8):1218-26. doi: 10.2967/jnumed.111.090902. Epub 2011 Jul 15.

PMID:
21764801
[PubMed - indexed for MEDLINE]
Free Article
2.

[Current topics about mild cognitive impairment (MCI)].

Yamamoto Y.

Seishin Shinkeigaku Zasshi. 2011;113(6):584-92. Review. Japanese.

PMID:
21815470
[PubMed - indexed for MEDLINE]
3.

Diagnostic accuracy of 18 F-FDG and 11 C-PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment.

Zhang S, Han D, Tan X, Feng J, Guo Y, Ding Y.

Int J Clin Pract. 2012 Feb;66(2):185-98. doi: 10.1111/j.1742-1241.2011.02845.x. Review.

PMID:
22257044
[PubMed - indexed for MEDLINE]
4.

Cerebral glucose metabolism in preclinical and prodromal Alzheimer's disease.

Herholz K.

Expert Rev Neurother. 2010 Nov;10(11):1667-73. doi: 10.1586/ern.10.136. Review.

PMID:
20977325
[PubMed - indexed for MEDLINE]
5.

Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.

Mosconi L.

Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):486-510. Review.

PMID:
15747152
[PubMed - indexed for MEDLINE]
6.

Positron emission tomography in at risk patients and in the progression of mild cognitive impairment to Alzheimer's disease.

Rinne JO, Någren K.

J Alzheimers Dis. 2010;19(1):291-300. doi: 10.3233/JAD-2010-1224. Review.

PMID:
20061645
[PubMed - indexed for MEDLINE]
7.

Use of FDG PET as an imaging biomarker in clinical trials of Alzheimer's disease.

Herholz K.

Biomark Med. 2012 Aug;6(4):431-9. doi: 10.2217/bmm.12.51. Review.

PMID:
22917145
[PubMed - indexed for MEDLINE]
8.

Perfusion SPECT and FDG-PET.

Herholz K.

Int Psychogeriatr. 2011 Sep;23 Suppl 2:S25-31. doi: 10.1017/S1041610211000937. Review.

PMID:
21729421
[PubMed - indexed for MEDLINE]
9.

Application of pet imaging to diagnosis of Alzheimer's disease and mild cognitive impairment.

Noble JM, Scarmeas N.

Int Rev Neurobiol. 2009;84:133-49. doi: 10.1016/S0074-7742(09)00407-3. Review.

PMID:
19501716
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Amyloid imaging.

Villemagne VL, Rowe CC.

Int Psychogeriatr. 2011 Sep;23 Suppl 2:S41-9. doi: 10.1017/S1041610211000895. Review.

PMID:
21729418
[PubMed - indexed for MEDLINE]
11.

Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature.

Bohnen NI, Djang DS, Herholz K, Anzai Y, Minoshima S.

J Nucl Med. 2012 Jan;53(1):59-71. doi: 10.2967/jnumed.111.096578. Epub 2011 Dec 15. Review.

PMID:
22173840
[PubMed - indexed for MEDLINE]
Free Article
12.

Integrating ADNI results into Alzheimer's disease drug development programs.

Cummings JL.

Neurobiol Aging. 2010 Aug;31(8):1481-92. doi: 10.1016/j.neurobiolaging.2010.03.016. Epub 2010 May 5. Review.

PMID:
20447734
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Geriatric medicine, Japanese Alzheimer's disease neuroimaging initiative and biomarker development.

Arai H, Okamura N, Furukawa K, Kudo Y.

Tohoku J Exp Med. 2010 Jun;221(2):87-95. Review.

PMID:
20467230
[PubMed - indexed for MEDLINE]
Free Article
14.

Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans.

Aisen PS, Petersen RC, Donohue MC, Gamst A, Raman R, Thomas RG, Walter S, Trojanowski JQ, Shaw LM, Beckett LA, Jack CR Jr, Jagust W, Toga AW, Saykin AJ, Morris JC, Green RC, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2010 May;6(3):239-46. doi: 10.1016/j.jalz.2010.03.006. Review.

PMID:
20451872
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Early detection of Alzheimer's disease with PET imaging.

Berti V, Osorio RS, Mosconi L, Li Y, De Santi S, de Leon MJ.

Neurodegener Dis. 2010;7(1-3):131-5. doi: 10.1159/000289222. Epub 2010 Mar 3. Review.

PMID:
20197691
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Imaging markers for Alzheimer disease: which vs how.

Frisoni GB, Bocchetta M, Chételat G, Rabinovici GD, de Leon MJ, Kaye J, Reiman EM, Scheltens P, Barkhof F, Black SE, Brooks DJ, Carrillo MC, Fox NC, Herholz K, Nordberg A, Jack CR Jr, Jagust WJ, Johnson KA, Rowe CC, Sperling RA, Thies W, Wahlund LO, Weiner MW, Pasqualetti P, Decarli C; ISTAART's NeuroImaging Professional Interest Area.

Neurology. 2013 Jul 30;81(5):487-500. doi: 10.1212/WNL.0b013e31829d86e8. Review.

PMID:
23897875
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Update on SPECT and PET in parkinsonism - part 2: biomarker imaging of cognitive impairment in Lewy-body diseases.

Meyer PT, Frings L, Hellwig S.

Curr Opin Neurol. 2014 Aug;27(4):398-404. doi: 10.1097/WCO.0000000000000107. Review.

PMID:
24978635
[PubMed - indexed for MEDLINE]
18.

Utility of imaging for nutritional intervention studies in Alzheimer's disease.

de Wilde MC, Kamphuis PJ, Sijben JW, Scheltens P.

Eur J Pharmacol. 2011 Sep;668 Suppl 1:S59-69. doi: 10.1016/j.ejphar.2011.07.011. Epub 2011 Jul 27. Review.

PMID:
21816137
[PubMed - indexed for MEDLINE]
19.

Molecular PET imaging in multicenter Alzheimer's therapeutic trials: current trends and implementation strategies.

Seibyl J, Zubal IG, Jennings D, Marek K, Doraiswamy PM.

Expert Rev Neurother. 2011 Dec;11(12):1783-93. doi: 10.1586/ern.11.168. Review.

PMID:
22091601
[PubMed - indexed for MEDLINE]
20.

Peripheral antioxidant markers in mild cognitive impairment and its progression to dementia.

Panza F, Solfrizzi V, Seripa D, Imbimbo BP, Pilotto A, Frisardi V.

J Alzheimers Dis. 2010;21(4):1179-83. Review.

PMID:
21504127
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk